Obesity and the renin– angiotensin–aldosterone system

References

• WHO Consultation on Obesity. Obesity – Preventing and Managing the Global Epidemic. Geneva, Switzerland, 3–5 June (1997).
   Google Scholar
• Han TS, Van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Brit. Med. J. 311, 1401–1405 (1995).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. (INTERHEART study investigators). Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366, 1640–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162, 1867–1872 (2002).
   PubMed Web of Science ®Google Scholar
• Hall JE, Henegar JR, Dwyer TM et al. Is obesity a major cause of chronic kidney disease? Adv. Ren. Replace. Ther. 11, 41–54 (2004).
   PubMedGoogle Scholar
• Hall JE. The kidney, hypertension, and obesity. Hypertension 41, 625–633 (2003).
   PubMed Web of Science ®Google Scholar
• Rocchini AP. Cardiovascular regulation in obesity-induced hypertension. Hypertension 19(Suppl.), I56–I60 (1992).
   PubMed Web of Science ®Google Scholar
• Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects: effects of saline load. Hypertension 23(Suppl.), I20–I24 (1994).
   Google Scholar
• Dahl LK, Silver L, Christie RW. The role of salt in the fall of blood pressure accompanying reduction in obesity. N. Engl. J. Med. 258, 1186–1192 (1958).
   PubMed Web of Science ®Google Scholar
• Rocchini AP, Key J, Bondie D et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 321, 580–585 (1989).
   PubMed Web of Science ®Google Scholar
• Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J. Clin. Invest. 95, 948–953 (1995).
   PubMed Web of Science ®Google Scholar
• Cooper R, McFarlane Anderson N, Bennett FI et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J. Hum. Hypertens. 11, 107–111 (1997).
   PubMed Web of Science ®Google Scholar
• Cooper R, Forrester T, Ogunbiyi O, Muffinda J. (ICSHIB Investigators). Angiotensinogen levels and obesity in four black populations. J. Hypertens. 16, 571–575 (1998).
   PubMed Web of Science ®Google Scholar
• Umemura S, Nyui N, Tamura K et al. Plasma angiotensinogen concentrations in obese patients. Am. J. Hypertens. 10, 629–633 (1997).
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 7, 355–362 (1999).
   PubMedGoogle Scholar
• Licata G, Scaglione R, Ganguzza A et al. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am. J. Hypertens. 7, 314–320 (1994).
   PubMed Web of Science ®Google Scholar
• Boustany CM, Bharadwaj K, Daugherty A et al. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R943–R949 (2004).
   PubMed Web of Science ®Google Scholar
• Engeli S, Böhnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45, 356–362 (2005).
   PubMed Web of Science ®Google Scholar
• Schorr U, Blaschke K, Turan S et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475–1480 (1998).
   PubMed Web of Science ®Google Scholar
• Uckaya G, Ozata M, Sonmez A et al. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm. Metab. Res. 31, 435–438 (1999).
   PubMed Web of Science ®Google Scholar
• Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am. J. Hypertens. 7, 886–893 (1994)
   PubMed Web of Science ®Google Scholar
• Vaz M, Jennings G, Turner A et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96, 3423–3429 (1997).
   PubMed Web of Science ®Google Scholar
• Grekin RJ, Ngarmukos CO, Williams DM, Supiano MA. Renal norepinephrine spillover during infusion of nonesterified fatty acids. Am. J. Hypertens. 18, 422–426 (2005).
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Morgan DA, Morgan GM et al. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54, 2012–2018 (2005).
   Google Scholar
• Eikelis N, Lambert G, Wiesner G et al. Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am. J. Physiol. Endocrinol. Metab. 286, E744–E752 (2004).
   Google Scholar
• Goodfriend TL, Ball DL, Egan BM et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43, 358–363 (2004).
   Google Scholar
• Couillard C, Ruel G, Archer WR et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab. 90, 6454–6459 (2005).
   PubMed Web of Science ®Google Scholar
• Hattori Y, Akimoto K, Gross SS et al. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 48, 1066–1074 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. USA. 100, 14211–14216 (2003).
   PubMed Web of Science ®Google Scholar
• Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nature. Clin. Pract. Cardiovasc. Med. 1, 42–47 (2004).
   PubMedGoogle Scholar
• Tamura K, Umemura S, Yamakawa T et al. Modulation of tissue angiotensinogen gene expression in genetically obese hypertensive rats. Am. J. Physiol. Reg. Integr. Comp. Physiol. 272, R1704–R1711 (1997).
   Google Scholar
• Barton M, Carmona R, Morawietz H et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 35, 329–336 (2000).
   PubMed Web of Science ®Google Scholar
• Xu ZG, Lanting L, Vaziri ND et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 111, 1962–1969 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmed SB, Fisher NDL, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 46, 1316–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Lifton RP, Hollenberger NK et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J. Hypertens. 14, 199–207 (1996).
   PubMed Web of Science ®Google Scholar
• Engeli S, Schling P, Gorzelniak K et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 35, 807–825 (2003).
   PubMed Web of Science ®Google Scholar
• Schling P, Schäfer T. Human adipose cells keep tight control on the angiotensin II levels in their vicinity. J. Biol. Chem. 277, 48066–48075 (2002).
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Adams F et al. Adipose tissue metabolism and CD11b expression on monocytes in obese hypertensives. Hypertension 46, 130–136 (2005).
   PubMed Web of Science ®Google Scholar
• Gorzelniak K, Engeli S, Janke J et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J. Hypertens. 20, 965–973 (2002).
   PubMed Web of Science ®Google Scholar
• Giacchetti G, Faloia E, Mariniello B et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15, 381–388 (2002).
   PubMed Web of Science ®Google Scholar
• Faloia E, Gatti C, Camilloni MA et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J. Endocrinol. Invest. 25, 309–314 (2002).
   PubMed Web of Science ®Google Scholar
• Davis D, Liyou N, Lockwood D, Johnson A. Angiotensinogen genotype, plasma protein and mRNA concentration in isolated systolic hypertension. Clin. Genet. 61, 363–368 (2002).
   Google Scholar
• Prat-Larquemin L, Oppert JM, Clement C et al. Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients. Obes. Res. 12, 556–561 (2004).
   PubMedGoogle Scholar
• Van Harmelen V, Elizalde M, Ariapart P et al. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int. J. Obes. 24, 673–678 (2000).
   Google Scholar
• Van Harmelen V, Ariapart P, Hoffstedt J et al. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8, 337–341 (2000).
   PubMedGoogle Scholar
• Hainault I, Nebout G, Turban S et al. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am. J. Physiol. 282, E59–E66 (2002).
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am. J. Physiol. 286, E891–E895 (2004).
   Google Scholar
• Massiera F, Bloch-Faure M, Ceiler D et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15, 2727–2729 (2001).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Yamamoto H, Kenyon CJ et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112, 83–90 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai YS, Kim HJ, Takahashi N et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest. 114, 240–249 (2004).
   PubMed Web of Science ®Google Scholar
• Harte A, McTernan P, Chetty R et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111, 1954–1961 (2005).
   PubMed Web of Science ®Google Scholar
• Janke J, Engeli S, Gorzelniak K et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51, 1699–1707 (2002).
   PubMed Web of Science ®Google Scholar
• Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie 85, 1219–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Janke J, Gorzelniak K et al. Angiotensin blockade prevents Type 2 diabetes by formation of fat cells. Hypertension 40, 609–611 (2002).
   PubMed Web of Science ®Google Scholar
• Katovich MJ, Pachori A. Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. Diabetes Obes. Metab. 2, 3–14 (2000).
   PubMed Web of Science ®Google Scholar
• Kouyama R, Suganami T, Nishida J et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1-α receptor. Endocrinology 146, 3481–3492 (2005).
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Even P, Bloch-Faure M et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54, 991–999 (2005).
   PubMed Web of Science ®Google Scholar
• Cassis L, Helton M, English V, Burke G. Angiotensin II regulates oxygen consumption. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R445–R453 (2002).
   PubMed Web of Science ®Google Scholar
• Kim S, Dugail I, Standridge M et al. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c. Biochem. J. 357, 899–904 (2001).
   PubMed Web of Science ®Google Scholar
• Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 50, 468–472 (2001).
   PubMed Web of Science ®Google Scholar
• Hennes MMI, O’Shaughnessy IM, Kelly TM et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals – role of the renin-angiotensin system. Hypertension 28, 120–126 (1996).
   PubMed Web of Science ®Google Scholar
• Boschmann M, Ringel J, Klaus S, Sharma AM. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes. Res. 9, 486–491 (2001).
   PubMedGoogle Scholar
• Boschmann M, Jordan J, Adams F et al. Tissue-specific response to interstitial angiotensin II in humans. Hypertension 41, 37–41 (2003).
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Adams F et al. Influences of AT1 receptor blockade on tissue metabolism in obese men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R219–R223 (2006).
   Google Scholar
• Goossens GH, Blaak EE, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J. Clin. Endocrinol. Metab. 89, 2690–2696 (2004).
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939–949 (2005).
   PubMed Web of Science ®Google Scholar
• Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes. Res. 13, 969–973 (2005).
   PubMedGoogle Scholar
• Kim S, Whelan J, Claycombe K et al. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J. Nutr. 132, 1135–1140 (2002).
   PubMed Web of Science ®Google Scholar
• Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 145, 169–174 (2004).
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Klein J, Neumann S et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 290, 1084–1092 (2002).
   PubMed Web of Science ®Google Scholar
• Clasen R, Schupp M, Foryst-Ludwig A et al. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46, 137–143 (2005).
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42, 76–81 (2003).
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109, 2054–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43, 993–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Masuzaki H, Tanaka T. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 (2004).
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Takizawa H et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 22, 1977–1982 (2004).
   PubMed Web of Science ®Google Scholar
• Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37, 1336–1340 (2001).
   PubMed Web of Science ®Google Scholar
• Skurk T, Lee YM, Nicuta-Rolfs TO et al. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes. Metab. 6, 56–62 (2004).
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Conlin PR, Macko RF et al. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. J. Hum. Hypertens. 16, 391–397 (2002).
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Klein J, Lossner U, Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor-α, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm. Metab. Res. 35, 147–152 (2003).
   PubMed Web of Science ®Google Scholar
• Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-κB. Arterioscler. Thromb. Vasc. Biol. 24, 1199–1203 (2004).
   PubMed Web of Science ®Google Scholar
• Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 111, 343–348 (2005).
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H. European trial on olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110, 1103–1107 (2004).
   PubMed Web of Science ®Google Scholar
• Tuck ML, Sowers J, Dornfeld L et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 304, 930–933 (1981).
   PubMed Web of Science ®Google Scholar
• Blaufox MD, Lee HB, Davis B et al. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. J. Am. Med. Assoc. 267, 1221–1225 (1992).
   Web of Science ®Google Scholar
• Harp JB, Henry SA, DiGirolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes. Res. 10, 985–990 (2002).
   PubMedGoogle Scholar
• Sowers JR, Nyby M, Stern N et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 4, 686–691 (1982).
   PubMed Web of Science ®Google Scholar
• Hegele RA, Brunt JH, Connelly PW. Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation 92, 1089–1093 (1995).
   PubMed Web of Science ®Google Scholar
• Rankinen T, Gagnon J, Perusse L et al. Body fat, resting and exercise blood pressure and the angiotensinogen M235T polymorphism: the heritage family study. Obes. Res. 7, 423–430 (1999).
   PubMedGoogle Scholar
• Ishigami T, Tamura K, Fujita T et al. Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I. Hypertension 34, 430–434 (1999).
   PubMed Web of Science ®Google Scholar
• Tiago AD, Samani NJ, Candy GP et al. Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension. Circulation 106, 1483–1487 (2002).
   PubMed Web of Science ®Google Scholar
• Strazzullo P, Iacone R, Iacoviello L et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann. Intern. Med. 138, 17–23 (2003).
   PubMed Web of Science ®Google Scholar
• Hunt SC, Cook NR, Oberman A et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 32, 393–401 (1998).
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Colombo M et al. Body weight reduwild-typection, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 97, 2037–2042 (1998).
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Lambert EA, Lambert GW et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J. Clin. Endocrinol. Metab. 90, 5998–6005 (2005).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Wilson AC, Hooper WC et al. Association of ACE DD genotype with blood pressure sensitivity to weight loss. Am. Heart J. 144, 625–629 (2002).
   PubMed Web of Science ®Google Scholar
• Scheen AF. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64, 2537–2565 (2004)
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Holman R et al for the DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 47, 1519–1527 (2004).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Califf R, Holman R et al. Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR. Eur. Heart J. 25(Suppl.), 239 (2004).
   Google Scholar
• The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am. Heart J. 148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar